<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RESCULA- unoprostone isopropyl solution/ drops </strong><br>Sucampo Pharma Americas, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use RESCULA safely and effectively. See full prescribing information for RESCULA.<br><br>
			Rescula (unoprostone isopropyl ophthalmic solution) 0.15%<br>
			Initial U.S. Approval: 2000<br></span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Rescula (unoprostone isopropyl ophthalmic solution) 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>. <a href="#SB0101abfcb51-4865-11e2-bcfd-0800200c9a66">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul><li>One drop in the affected eye(s) twice daily <a href="#SB0201abfcb51-4865-11e2-bcfd-0800200c9a66">(2)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Unoprostone isopropyl ophthalmic solution, 1.5 mg/mL <a href="#SB0301abfcb51-4865-11e2-bcfd-0800200c9a66">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to unoprostone isopropyl or any of the excipients <a href="#SB0401abfcb51-4865-11e2-bcfd-0800200c9a66">(4)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Rescula has been reported to increase <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris <a href="#SB0511abfcb51-4865-11e2-bcfd-0800200c9a66">(5.1)</a>
</li>
<li>Rescula has been reported to increase <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the periorbital tissues and eyelashes <a href="#SB0521abfcb51-4865-11e2-bcfd-0800200c9a66">(5.2)</a>
</li>
<li>Rescula should be used with caution in patients with active intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> because the <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may be exacerbated <a href="#SB0531abfcb51-4865-11e2-bcfd-0800200c9a66">(5.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>Most common adverse reactions (incidence 10–25%) are burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> upon drug instillation, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, increased length of eyelashes and injection <a href="#SB0611abfcb51-4865-11e2-bcfd-0800200c9a66">(6.1)</a>
</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sucampo Pharma Americas at 1-855-RESCULA (1-855-737-2852) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
<p class="Highlighta">      </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 11/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Lid <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Contamination of Tip and Solution</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Use with Contact Lenses</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5  Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14  CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 Handling the Bottle</a></h2>
<h2><a href="#section-13.2" class="toc">17.2 Potential for Iris Darkening</a></h2>
<h2><a href="#section-13.3" class="toc">17.3 Potential For Eyelid Skin Darkening </a></h2>
<h2><a href="#section-13.4" class="toc">17.4 Use with Contact Lenses</a></h2>
<h2><a href="#section-13.5" class="toc">17.5 Multiple Therapies</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="SB0101abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">Rescula (unoprostone isopropyl ophthalmic solution) 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="SB0201abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dosage is one drop in the affected eye(s) twice daily.</p>
<p>Rescula may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If two drugs are used, they should be administered at least five (5) minutes apart<span class="Italics">[see Patient Counseling Information <a href="#SB1751abfcb51-4865-11e2-bcfd-0800200c9a66">(17.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="SB0301abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Unoprostone isopropyl ophthalmic solution, 1.5 mg/mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="SB0401abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">Rescula is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to unoprostone isopropyl or any other ingredient in this product.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="SB0501abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB0511abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span></h2>
<p class="First">Unoprostone isopropyl ophthalmic solution may gradually increase the <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris. The <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> change is believed to be due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. The long term effects of increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> are not known. Iris color changes seen with administration of unoprostone isopropyl ophthalmic solution may not be noticeable for several months to years. Typically, the brown <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. Treatment with Rescula solution can be continued in patients who develop noticeably increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>.</p>
<p>Patients who receive treatment with Rescula should be informed of the possibility of increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> <span class="Italics">[see Patient Counseling Information <a href="#SB1721abfcb51-4865-11e2-bcfd-0800200c9a66">(17.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB0521abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Lid <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span></h2>
<p class="First">Unoprostone isopropyl has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes.  The <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> is expected to increase as long as unoprostone isopropyl is administered, but has been reported to be reversible upon discontinuation of unoprostone isopropyl ophthalmic solution in most patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB0531abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></h2>
<p class="First">Rescula should be used with caution in patients with active intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (e.g., <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>) because the <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may be exacerbated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB0541abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span>, including <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>, has been reported. Rescula should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB0551abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Contamination of Tip and Solution</h2>
<p class="First">To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of multiple-dose containers of topical ophthalmic products <span class="Italics">[see Patient Counseling Information <a href="#SB1711abfcb51-4865-11e2-bcfd-0800200c9a66">(17.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB0561abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Use with Contact Lenses</h2>
<p class="First">Rescula contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration <span class="Italics">[see Patient Counseling Information <a href="#SB1741abfcb51-4865-11e2-bcfd-0800200c9a66">(17.4)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="SB0601abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34092-7">
<a name="SB0611abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>In clinical studies, the most common ocular adverse reactions with use of Rescula were burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> upon drug instillation, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, increased length of eyelashes, and injection. These were reported in approximately 10–25% of patients. Approximately 10–14% of patients were observed to have an increase in the length of eyelashes (≥ 1 mm) at 12 months, while 7% of patients were observed to have a decrease in the length of eyelashes.</p>
<p>Ocular adverse reactions occurring in approximately 5–10% of patients were <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="376125" conceptname="Disorder of eyelid">eyelid disorder</span>, foreign body sensation, and <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> disorder.</p>
<p>Ocular adverse reactions occurring in approximately 1–5% of patients were <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4270897" conceptname="Corneal lesion">corneal lesion</span>, discharge from the eye, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, irritation, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="313498" conceptname="Vitreous strands">vitreous disorder</span>.</p>
<p>Other ocular adverse reactions reported in less than 1% of patients were acute elevated intraocular pressure, <span class="product-label-link" type="condition" conceptid="372633" conceptname="Deutan defect">color blindness</span>, <span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">corneal deposits</span>, <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span>, <span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">corneal opacity</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, hyperpigmentation of the eyelid, increased number of eyelashes, iris hyperpigmentation, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>.</p>
<p>The most frequently reported nonocular adverse reaction associated with the use of Rescula in the clinical trials was flu-like syndrome that was observed in approximately 6% of patients. Nonocular adverse reactions reported in the 1–5% of patients were <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB0621abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Rescula.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.</p>
<p>Voluntary reports of adverse reactions occurring with the use of Rescula include <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>.</p>
<p>There have been rare spontaneous reports with a different formulation of unoprostone isopropyl (0.12%) of <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">chemosis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="SB0801abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-7"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="SB0811abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-7.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First">Pregnancy Category C</p>
<p>Teratogenic effects: There were no teratogenic effects observed in rats and rabbits up to 5 and 0.3 mg/kg/day (approximately 1,000 and 60 fold the recommended human dose of 0.005 mg/kg/day in the rat and rabbit, respectively). There was an increase in the incidence of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriages</span> and a decrease in live birth index in rats administered unoprostone isopropyl during organogenesis at subcutaneous doses of 5 mg/kg. There was an increase in incidence of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriages</span> and resorptions and a decrease in the number of live fetuses in rabbits administered unoprostone isopropyl during organogenesis at subcutaneous doses of 0.3 mg/kg. The no observable adverse effect level (NOAEL) for embryofetal toxicity in rats and rabbits was 2 and 0.1 mg/kg (approximately 400 and 20 fold the recommended human dose of 0.005 mg/kg/day in the rat and rabbit, respectively).</p>
<p>There was an increase in incidence of <span class="product-label-link" type="condition" conceptid="4086393" conceptname="Premature delivery">premature delivery</span>, a decrease in live birth index, and a decrease in weight at birth and through postpartum Day 7 in rats administered unoprostone isopropyl during late gestation through postpartum Day 21 at subcutaneous doses of 1.25 mg/kg. In addition, pups from rats administered 1.25 mg/kg subcutaneously exhibited delayed growth and development characterized by delayed incisor <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span> and eye opening. There was an increase in the number of stillborn pups and a decrease in perinatal survival in rats administered unoprostone isopropyl during late gestation through weaning at subcutaneous doses of ≥ 0.5 mg/kg. The NOAEL for pre- and postnatal toxicity in rats was 0.2 mg/kg (approximately 40 fold the recommended human dose of 0.005 mg/kg/day).</p>
<p>There are no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, Rescula should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="SB0831abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether Rescula is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Rescula is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="SB0841abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-7.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="SB0851abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-7.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and other adult patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="SB1101abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-8"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">Rescula (unoprostone isopropyl ophthalmic solution) 0.15% is a synthetic docosanoid. Unoprostone isopropyl has the chemical name isopropyl (+)-(<span class="Italics">Z</span>)-7-[(1<span class="Italics">R</span>,2<span class="Italics">R</span>,3<span class="Italics">R</span>,5<span class="Italics">S</span>)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate. Its molecular formula is C<span class="Sub">25</span>H<span class="Sub">44</span>O<span class="Sub">5</span> and its chemical structure is:</p>
<div class="Figure"><img alt="Chemical structure of unoprostone isopropyl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53d05ced-51dd-11de-8a39-0800200c9a66&amp;name=rescula-figure-1.jpg"></div>
<p>Unoprostone isopropyl is a clear, colorless, viscous liquid that is very soluble in acetonitrile, ethanol, ethyl acetate, isopropanol, dioxane, ether, and hexane. It is practically insoluble in water. Rescula (unoprostone isopropyl ophthalmic solution) 0.15% is supplied as a sterile, isotonic, buffered, aqueous solution of unoprostone isopropyl with a pH of 5.0–6.5 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of 235–300 mOsmol/kg.</p>
<p>Each mL of Rescula contains 1.5 mg of unoprostone isopropyl. Benzalkonium chloride 0.015% is added as a preservative. Inactive ingredients are mannitol, polysorbate 80, edetate disodium, sodium hydroxide or hydrochloric acid (to adjust pH), and water for injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="SB1201abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-9"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="SB1211abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-9.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Rescula is believed to reduce elevated intraocular pressure (IOP) by increasing the outflow of aqueous humor through the trabecular meshwork. Unoprostone isopropyl (UI) may have a local effect on BK (Big Potassium) channels and ClC-2 chloride channels, but the exact mechanism is unknown at this time.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="SB1231abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-9.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First"><span class="Bold">Absorption</span></p>
<p>After application to the eye, unoprostone isopropyl is absorbed through the cornea and conjunctival epithelium where it is hydrolyzed by esterases to unoprostone free acid.</p>
<p>A study conducted with 18 healthy volunteers dosed bilaterally with unoprostone isopropyl ophthalmic solution twice daily for 14 days demonstrated little systemic absorption of unoprostone isopropyl. The systemic exposure of its metabolite unoprostone free acid was minimal following the ocular administration. Mean peak unoprostone free acid concentration was less than 1.5 ng/mL. Little or no accumulation of unoprostone free acid was observed.</p>
<p><span class="Bold">Metabolism</span></p>
<p>Following ocular application, unoprostone isopropyl is hydrolyzed by esterases in the cornea to its biological active metabolite, unoprostone free acid. Unoprostone free acid is further metabolized to several inactive metabolites with lower molecular weight and increased polarity via ω- or β-oxidation. No secondary conjugation is found and no significant effect on hepatic microsomal enzyme activity has been observed.</p>
<p><span class="Bold">Elimination</span></p>
<p>Elimination of unoprostone free acid from human plasma is rapid, with a half-life of 14 minutes. Plasma levels of unoprostone free acid dropped below the lower limit of quantitation (&lt; 0.25 ng/mL) 1 hour following ocular instillation. The metabolites are excreted predominately in urine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="SB1301abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-10"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="SB1311abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-10.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Unoprostone isopropyl was not carcinogenic in rats administered oral doses up to 12 mg/kg/day for up to 2 years (approximately 580 and 240 fold the recommended human dose of 0.005 mg/kg/day based on AUC<span class="Sub">0–24</span> in male and female rats, respectively).</p>
<p>Under the conditions tested, unoprostone isopropyl and unoprostone free acid were neither mutagenic in an Ames assay nor clastogenic in a chromosome aberration assay in Chinese hamster lung–derived fibroblast cells. Under the conditions tested, unoprostone isopropyl was not genotoxic in a mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutation assay or clastogenic in an <span class="Italics">in vivo</span> chromosomal aberration test in mouse bone marrow.</p>
<p>Unoprostone isopropyl did not impair male or female fertility in rats at subcutaneous doses up to 50 mg/kg (approximately 10,000 fold the recommended human dose of 0.005 mg/kg/day).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="SB1401abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-11"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">In six (6) month randomized controlled clinical studies in patients with a mean baseline intraocular pressure of 23 mmHg, Rescula lowered intraocular pressure by approximately 3–4 mmHg throughout the day. Rescula appeared to lower intraocular pressure without affecting cardiovascular or pulmonary function.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="SB1601abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-12"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Rescula (unoprostone isopropyl ophthalmic solution) 0.15% is supplied sterile in a low-density polyethylene bottle with a low-density polyethylene dropper tip, a turquoise polypropylene closure, and a clear tamper-evident shrinkband.</p>
<p>5 mL in a 7.5 mL bottle NDC 17350-015-05</p>
<p><span class="Bold">Storage:</span> Store between 2°–25°C (36°–77°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="SB1701abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-13"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB1711abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-13.1"></a><p></p>
<h2>17.1 Handling the Bottle</h2>
<p class="First">Patients should be instructed that the Rescula bottle must be maintained intact and to avoid allowing the tip of the bottle to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination of the bottle or applicator by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may result from using contaminated solutions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB1721abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-13.2"></a><p></p>
<h2>17.2 Potential for Iris Darkening</h2>
<p class="First">Patients should be advised about the potential for increased brown iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> which is likely to be permanent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB1731abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-13.3"></a><p></p>
<h2>17.3 Potential For Eyelid Skin Darkening </h2>
<p class="First">Patients should be informed about the possibility of eyelid skin darkening, which may be reversible after discontinuation of Rescula.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB1741abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-13.4"></a><p></p>
<h2>17.4 Use with Contact Lenses</h2>
<p class="First">Patients should be advised that Rescula contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of Rescula and may be reinserted 15 minutes following its administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB1751abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-13.5"></a><p></p>
<h2>17.5 Multiple Therapies</h2>
<p class="First">If more than one topical ophthalmic therapy is being used patients should be instructed to administer the drugs at least 5 minutes apart.</p>
<p><span class="Bold">Marketed by:</span></p>
<p>Sucampo Pharma Americas, LLC<br>Bethesda, MD 20814</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB1801abfcb51-4865-11e2-bcfd-0800200c9a66"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Final Sample Carton</span></p>
<p><img alt="Final Sample Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53d05ced-51dd-11de-8a39-0800200c9a66&amp;name=rescula-figure-2.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RESCULA 		
					</strong><br><span class="contentTableReg">unoprostone isopropyl solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17350-015</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>UNOPROSTONE ISOPROPYL</strong> (UNOPROSTONE) </td>
<td class="formItem">UNOPROSTONE ISOPROPYL</td>
<td class="formItem">1.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17350-015-05</td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021214</td>
<td class="formItem">01/07/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sucampo Pharma Americas, LLC
							(002879844)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fc3a7ee0-5684-11e2-a894-0002a5d5c51b</div>
<div>Set id: 53d05ced-51dd-11de-8a39-0800200c9a66</div>
<div>Version: 3</div>
<div>Effective Time: 20130104</div>
</div>
</div> <div class="DistributorName">Sucampo Pharma Americas, LLC</div></p>
</body></html>
